Important lessons in this respect derive from the field of cancer research, where instead of grouping patients by affected organ (e.g. breast cancer or colon cancer), we now recognize that molecular signatures such as BRCA1/2 mutations or BRAF-V600E alterations, that transcend tissue boundaries, can provide more effective treatment strategies across cancers [3]. This evidence concerns the gene BRCA1 and cancer.